Register now!
Login
OCTOBER 9-10, 2025
Professional HUB Hannover Medical Park
Hannover, Germany
Poster Exhibition | Delta Cure - 4th International Meeting |...
View and download the Posters, divided by topic, presented at...
Poster Exhibition
The Poster Sessions have been kindly supported by the German Foundation of Infection Research (DZIF)
A special thanks also goes to Altona diagnostics GmbH
for sponsoring the poster4you tool
which complementarily supported the upload and printing of the scientific posters.
HDV Epidemiology
P20
HBV-HDV Coinfection - Prevalence, Clinical, Epidemiological and Molecular Aspects in the western Brazilian Amazon
W. Braga, M. Berg, M. Rodgers, A. Da Costa, F. Averhoff, N. Ferreira, C. Silveira, E. Kallas, M. Castilho, Y. Rodrigues, M. Gouvea, L. Ribeiro, M. Thomazella, L. Honorato, T. Mendoza, S. Witkin, G. Cloherty, M.C. Mendes-Correa
P22
Hep-care-Javari - examples from the jungle as clue to the elimination
W.S.M. Braga, N. Vieira Barbosa, Y.K. Batista Rodigues, C. Nakua Mayuruna, M. da Costa Castilho
P23
High rates of advanced chronic liver disease in patients with chronic hepatitis D virus infection in Uzbekistan
M. Khodjaeva, A. Khikmatullaeva, N. Mirrakhimova, P. Huber, M. Gebel, H. Wedemeyer, E. Musabaev, L. Sandmann
P26
HDV Management Experience in Georgia
M. Zakalashvili, J. Zarkua, E. Tsirdava, T. Avalishvili, M. Chakhnashvili, D. Metreveli
P27
Enhancing Hepatitis D awareness among Hepatitis B carriers: an ongoing screening program
L.C. Ion, G.S. Gherlan, I.A. Condurache
P28
Anti-HDV and HDV RNA screening in High-Risk HBV-infected populations from Nigeria
I. Ifeorah, B. Bremer, Y. Musa Yusuf, J. Kahlhöfer, M. Anim, A. Ojonuga, Y. Abdulkadir, O. Oguntoye, O. Ariyo, A. Reinhardt, L. Abdulkareem, I. U. Garzali, U. Akpan, H. Wedemeyer, L. Sandmann
P33
Understanding the barriers to scaling up hepatitis delta responses - findings from a global survey
J. Hicks, C. James, C. Pokuah
P35
Epidemiology of hepatitis delta virus in Belgium: interim results of a prospective cross-sectional cohort study
M. Coessens, I. Roukaerts, J. Wawrzyniak, M. Steverlynck, M. Reda, M. Reynders, H. Orlent, H. Vanpoucke, C. De Vloo, J. Van Acker, T. Banica, E. Padalko, L. Lasser, A. Scohy, G. Zorzi, N. Yin, S. Goes, A. Van Dalem, P. Beckers, M-P. Hayette, S. Vandamme, S. Van den Wijngaert, J-P. Mulkay, N. Van Gasse, P. Bruynseels, K. Hoet, B. Van Herendael, W. Verlinden, M. Mukovnikova, A. Vodolazkaia, S. Van Gucht, T. Vanwolleghem
P37
Trends of advanced chronic liver disease among 17,711 persons in Mongolia during years 2015-2023
H. Kamal, G. Jargalsaikhan, S. Enkhtaivan, D. Bruce, K. Lindahl, B. Dashtseren, T. Ulziibadrakh, M. Batkhuu, P. Bat-Ulzii, S. Byambabaatar, S. Aleman, N.B. Dashdorj
P38
Model development for the estimation of hepatitis delta prevalence in the general population
H.R. Watson, A. Nizzardo, L. Nidiarci, E. Liusina, W.J. Alexander
Virology and Pathogenesis
P02
Viral and host diversity in Hepatitis B and Delta infection
Y.K. Batista-Rodrigues, M. da Costa Castilho, R. Santana Aguiar, R.P. de Souza, W.S.M. Braga
P03
Generation and characterization of HDV-specific antisera with respect to their application as specific and sensitive research and diagnostic tools
K. Thiyagarajah, S. Hein, J. Raupach, M. Knapp, C. Welsch, M. Glitscher, E. Görgülü, P. Stoffers, P. Lembeck, J. Trebicka, S. Ciesek, K.-H. Peiffer, E. Hildt
P04
Markers of HBV cccDNA transcriptional activity are changing during bulevirtide therapy - any impact on predicting therapy response?
I. Carey, J. Lok, Z. Cargill, M. Anderson, G. Cloherty, G. Dusheiko, K. Agarwal
P05
A cross-sectional, intrahepatic analysis of HBV and HDV markers in liver transplants of untreated and bulevirtide-treated patients with chronic Hepatitis Delta
E. Degasperi, C. Dibenedetto, M. Maggioni, D. Sambarino, E. Sguazzini, F. Facchetti, M.P. Anolli, M. Sagasta, S. Monico, P. Toniutto, C. Zöllner, F. Tacke, N. Semmo, M.F. Donato, P. Lampertico
P06
Does the endogenous interferon-I contribute to HDV genetic variability? An in vivo study with a superinfected mouse model
B. Pacin-Ruiz, G. Camps Ramón, J. Gregori, A. Vales Aranguren, C. Olague Micheltorena, D. Tabernero, A. Rando-Segura, M. Buti, F. Rodriguez-Frias, R. Ferrer Costa, G. González-Aseguinolaza, M.F. Cortese
P07
HDV sub-genotypes 1 is characterised by a high degree of genetic variability and can drive the selection of divergent genetic pathways modulating HDV replicative potential and cytolytic activity
L. Piermatteo, A. Magnapera, G. Torre, L. Carioti, S. D’Anna, L. Etogo, A. Bertoli, P. Paba, A. Olivero, E. Teti, A. Di Lorenzo, V. Malagnino, M. Iannetta, L. Baiocchi, S. Francioso, I. Lenci, U. Cillo, A. Vitale, G. Brancaccio, G. B. Gaeta, A. Ciancio, F. Ceccherini-Silberstein, S. Grelli, L. Sarmati, P. Lampertico, M. Rizzetto, G. P. Caviglia, R. Salpini, V. Svicher
P10
HBsAg composition as a biomarker for CHD treatment response
H. Rodemerk, M. Pfefferkorn, L. Drechsel, J. Seltmann, R. Winkler, S. Sopena Santisteve, M. Matz-Soja, M. Buti, P. Ingiliz, M. Brunetto, R. Heyne, P. Lampertico, D. Glebe, T. Berg, F. van Bömmel
P11
Co-infection with HDV is associated with increased serum markers of cccDNA core promoter activity: Insights from an ethnically diverse, real-world patient population
J. Lok, Z. Cargill, M. Anderson, G. Cloherty, G. Dusheiko, N. Wand, J. Harris, S. Tsukuda, J. McKeating, K. Agarwal, I. Carey
P12
HDV attenuates TNFα-mediated apoptosis in HBeAg-negative HBVexpressing cells independent of NF-κB signaling
P. Lembeck, K. Thiyagarajah, J. Sonnenberg, L. Büning, M. Glitscher, J. Trebicka, E. Hildt, K. Peiffer
P13
The IRF1-driven constitutive immunity restricts cell division-mediated spread
F. Lange, T. Pietschmann, A. Carpentier
P14
Circulating miRNA Signatures as Predictive Biomarkers of Virological Control and Treatment Response in Hepatitis Delta Virus Infection
J. Pérez Garreta, M.F. Cortese, A. Palom, J. Vico, D. Tabernero, A. Rando Segura, J.C. Ruiz Cobo, M. Riveiro Barciela, M. Buti
P16
Spatial profiling of HBV and HDV infection in human liver samples reveals reversible phenotype upon clearance
M. Saez-Palma, M. Buendia, T. Leonel, E. García-Pras, Á. Sanzo-Machuca, M. Acera, A. Pocurull, S. Battistella, S. Rodríguez-Tajes, S. Shalaby, A. Ojeda, A. Díaz, Y. Fundora, E. Mereu, X. Forns, S. Lens, A. Salas, M. Locatelli, S. Pérez-del-Pulgar
P17
A Syrian hamster model of HDV infection
E. Broeckhoven, F. Van Bavel, M. Smits, L. Degrauwe, M. Rasulova, H. Thibaut, L. Coelmont, Y. Debing, C. Van Den Haute, R. Gijsbers, K. Dallmeier
Diagnosis, Staging, and Disease progression
P01
Comparison of the clinical and immune-controlled characteristics of hepatocellular carcinoma caused by HBV and HDV
S. Glimmann, B. Heinrich, K. Deterding, K. Bock, B. Bremer, A. Kraft, M. Cornberg, H. Wedemeyer, A. Wranke
P15
Anti-hepatitis D virus (HDV) prevalences using lateral flow assay testing and HDV infections in the liver clinic of university hospital Heidelberg (Germany)
G.E. Gnouamozi, A. Groß, P. Schnitzler, L. Szewczenko, P. Michl, S. Urban, S. Nkongolo
P21
Is HBV/HDV-3 infection truly a different issue? – Clinical aspects and non-invasive predictors of compensated Advanced Chronic Liver Disease (cACLD) in a case series from the western Brazilian Amazon
W.S.M. Braga, A. Lais Bessa Maia, M. Tapajós Araújo, J.R. Di Tommaso Leão, L.C. de Lima Ferreira, L.C. Neves, F. Guedes Amorim, M. da Costa Castilho, A. dos Santos Pinto, C.M. Costa de Oliveira
P24
Development of Pan-Genotypic Rapid Immunochromatographic Tests for the Diagnosis of Hepatitis D
T.B. Lopes, F.F. Coelho, T.P. Roca, J.K.A. Oliveira, V. Delagarde, D.S. Vieira, R. T. Gazzinelli, F. Le Gal, A.P. Fernandes
P25
RoboGene HDV RNA Quantification Kit 3.0 – RUO | LoD, Linear Range & Performance Data Comparison with RoboGene HDV RNA Quantification Kit 2.0 – IvD
A. Reinhardt, Ch. Früchtel, B. Gey, B. Bremer, L. Sandmann, H. Wedemeyer, P. Lampertico, A. Callegaro, S. Renteria, E. Stelzl, H. Kessler, I. Lachmann
P29
Assay-dependent variability in HDV RNA undetectability rates during bulevirtide monotherapy in chronic Hepatitis Delta patients
M.P. Anolli, S. Uceda Renteria, E. Degasperi, F. Facchetti, D. Sambarino, M. Borghi, R. Perbellini, R. Soffredini, S. Monico, A. Callegaro, P. Lampertico
P30
Variability in HDV RNA detection highlights the need for diagnostic standardization in the bulevirtide era
V. Zulian, C. Taibi, A. Coppola, A. Bibbò, L. Federici, M. De Sanctis, S. Pauciullo, G. D'Offizi, E. Biliotti, F. McPhee, A.R. Garbuglia
P31
Risk of liver-related events associated with metabolic comorbidities among individuals with hepatitis delta infection
L.E. Telep, L.A. Patmore, L.S. Hong, A. Kose, A.W. Singer, A.P. Chokkalingam, H.A. Janssen, M.J. Sonneveld
P32
The experimental journey to accurate HDV RNA quantification with the AltoStar® HDV RT-PCR Kit 1.5
Marie T. Breuer, P. Rosenstock, S. Retzlaff, B. Duethorn, K. Rottengatter
P34
Evaluation of the Linear Range of the AltoStar® HDV RT-PCR Kit 1.5* using HDV specific RNA
S. Retzlaff, K. Rottengatter
P36
Diabetes, male gender, low HBsAg, and HDV RNA levels are factors associated with spontaneous HDV suppression in patients with HBV/HDV co-infection
H. Kamal, G. Jargalsaikhan, S. Enkhtaivan, K. Lindahl, B. Dashtseren, O. Lkhagva-Ochir, T. Ulziibadrakh, A. Bungert, N.B. Dashdorj, S. Aleman
P39
Hepatitis D: high burden of cirrhosis and portal hypertension, systemic inflammation and IL28B C/C as unfavorable factors
M. Hintersteininger, M. Schwarz, C. Schwarz, D. J.M. Bauer, M. Panzer, M. Strasser, S. Reiter, L. Dorn, A. Maieron, A. Moschen, E. Aigner, M. Trauner, A.F. Stättermayer, M. Mandorfer, H. Zoller, M. Gschwantler, T. Reiberger, M. Jachs
P40
Profile of Liver Transplant Candidates on the National Waiting List in the Republic of Moldova
A. Peltec, D. Buga, N. Taran, A. Hotineanu
P41
Individuals with hepatitis delta infection may experience a greater burden of rheumatoid arthritis than those with hepatitis B mono-infection
A. Stead, L. Telep, W. Wang, B. Mitchell, A. Lichtman, D. Manuilov, A. Singer
P42
Course and clinical outcomes of chronic Hepatitis Delta: a longitudinal analysis of 565 patients from the D-SOLVE and HDV-1000 consortia
H. Kamal, E. Degasperi, M. Radu, D. Sambarino, A. Wranke, I. Carey, M. Subic-Levrero, K. Lindahl, L. Sandmann, P. Dörge, J. Kahlhöfer, F. Zoulim, K. Agarwal, S. Aleman, F.A. Caruntu, P. Lampertico, H. Wedemeyer
P43
CSE-MRI is a novel MRI-based technique for the diagnosis of liver fibrosis in patients with chronic hepatitis D
C. Stern, J. Sellier, R. Ouji, K. Hammami, R. Winzenrieth, P. Labauge
P49
Suboptimal performances of Baveno VII and AASLD 2024 criteria for detecting clinically significant portal hypertension with varices in untreated patients with HDV cirrhosis
M.P. Anolli, E. Degasperi, G. Tosetti, M. Lucà, L. Gheorghe, A. Loglio, A. Ciancio, G. D’Offizi, M. Jachs, C. Schramm, M.R. Brunetto, F. Van Bömmel, S. Zaltron, L. Turco, C. Zöllner, T.A. Santantonio, I. Carey, A. Federico, L. Sarmati, M. Buti, M. Cardoso, F. Morisco, M. Papatheodoridi, F.P. Russo, A. Mangia, P. Toniutto, N. Coppola, C. Dietz-Fricke, J. Dumortier, E.G. Giannini, E. Rosselli Del Turco, S. Aleman, S. De Nicola, P. Gatti, M. Maracci, L. Marinaro, M. Milella, A. Pellicelli, B. Pinchera, M. Puoti, D. Roulot, L.S. Crocè, I. Maida, U. Merle, A. Pan, P. Torre, F. Pileri, A. Romano, M. Tonnini, P. Vitiello, R. Zampino, P. Lampertico on behalf of the SAVE-D and D-SHIELD investigators
P61
Healthcare Resource Utilisation and Costs Associated With Hepatitis Delta Virus Infection Compared With Hepatitis B Virus Monoinfection Prior to Death Among Adults in Italy in Inpatient and Outpatient Settings
P. Lampertico, V. Perrone, L. Degli Esposti, M. Leogrande, C. Kim, M. Rock
Current and new antiviral treatments
P08
Bulevirtide reduces HDV viral load and hepatocyte-derived innate immune responses in patients with chronic hepatitis D and humanized mice with an enriched amount of HDV-mono-infected hepatocytes
A. Volmari, T. Volz, L. Allweiss, L. Bergmann, J. Chen, J.H. Bockmann, M. Lütgehetman, D. Manuilov, B. Downie, J.J. Wallin, S.P. Fletcher, M.M. Holdorf, R.C. Muench, M. Dandri
P44
SOLSTICE Week 24 subgroup analysis: Impact of baseline viral parameters and cirrhosis status on virological and biochemical responses in participants with chronic hepatitis delta virus infection treated with tobevibart and elebsiran
A. Jucov, T. Asselah, A. Streinu-Cercel, E. Gane, H. Wedemeyer, P. Lampertico, M.A. Chattergoon, B. Bullard, C. Huang, R. Acosta, C. Pilowa, T. Correll, C. Hwang, K. Agarwal
P45
Treatment response to bulevirtide is linked to amelioration of portal hypertension in patients with chronic hepatitis D
L. Sandmann, M. Jachs, T.L. Tergast, L. Hartl, B. Bremer, M.A. Kabelitz, M. Schwarz, J.F.M. Egge, L. Balcar, B.S. Hofer, C.S. Falk, A.F. Stättermayer, M. Cornberg, M. Trauner, K. Deterding, M. Mandorfer, H. Wedemeyer, T. Reiberger, B. Maasoumy
P46
IB-001 is a Partial Agonist of the Type 1 Interferon Pathway that Exhibits Potent Antiviral Activity against HBV and HDV with the Potential for an Improved Safety Profile
W. Blair, C. Kurokawa, N. Sallada, R. Wang, Q. Liu, L. Chen, M. Bolton, E. Cho, A. Romero, M. Mann, A. Mercer, Y.M. Loo, C. Hwang
P47
Antisense oligonucleotide-based strategy to target hepatitis delta virus infections
C. Pons, E.R. Verrier, A. Bhattacharya, K. Passow, L. Degrauwe, A. Stoycheva, L. Blatt, J. Symons, A. Jekle, V. Rajwanshi, D.B. Smith, Y. Debing, D. Durantel, J. Lucifora
P48
Final results of MYR301: A randomised Phase 3 study evaluating the efficacy and safety of up to 144 weeks of bulevirtide monotherapy for chronic hepatitis delta and 96 weeks of posttreatment follow-up
H. Wedemeyer, S. Aleman, A. Blank, P. Andreone, P. Bogomolov, V. Chulanov, N. Mamonova, N. Geyvandova, V. Morozov, O. Sagalova, T. Stepanova, A. Berger, S. Ciesek, A. Lichtman, D. Manuilov, R.C. Mercier, S. Arterburn, F. Christian-Cox, S. Tseng, A. Osinusi, J. Schulze zur Wiesch, M. Cornberg, S. Zeuzem, M.R. Brunetto, P. Lampertico
P50
The effectiveness of bulevirtide monotherapy is similar in chronic Hepatitis Delta patients with and without cirrhosis: results from the prospective multicenter D-SHIELD study
M.P. Anolli, E. Degasperi, G. D’Offizi, A. Rianda, A. Loglio, M. Viganò, A. Ciancio, Y. Troshina, M.R. Brunetto, B. Coco, S. Zaltron, A. Cambianica, M. Milella, E. Rosselli Del Turco, L. Turco, L. Sarmati, P. Toniutto, A. Gasbarrini, L. Marinaro, F.P. Russo, A. Gori, I. Maida, A. Federico, T.A. Santantonio, E.G. Giannini, I. Cacciola, F. Morisco, A. Mangia, S. De Nicola, A. Romano, M. Maracci, B. Pinchera, S.L. Crocè, F. Pileri, R. Zampino, M. Persico, P. Pozzoni, A. Pan, A. Pellicelli, N. Coppola, M. Tonnini, E. Grassi, A. Soria, P. Caraceni, I. Arena, V. Esposito, P. Vitiello, M. Puoti, P. Lampertico
P51
Predictors of Undetectable Hepatitis Delta Virus RNA at 48 Weeks After End of Treatment With Bulevirtide Monotherapy in the MYR 301 Study
S. Aleman, M. Brunetto, A. Blank, P. Andreone, P. Bogomolov, V. Chulanov, N. Mamonova, N. Geyvandova, V. Morozov, O. Sagalova, T. Stepanova, A. Lichtman, R.C. Mercier, D. Manuilov, S. Arterburn, J. Schulze zur Wiesch, M. Cornberg, S. Zeuzem, P. Lampertico, H. Wedemeyer
P52
Overview of Patients with Hepatitis D Infection Treated with Bulevirtide at National Institute for Infectious Diseases “Prof. Dr. Matei Bals” (INBIMB), Romania
M.N. Radu, C. Tudoran, R.B. Băloi, F.A. Căruntu
P53
Bulevirtide—more than an entry inhibitor?
M. Glitscher, K. Thiyagarajah, A. Schollmeier, J. Geyer, K.H. Peiffer, E. Hildt
P54
Maintained HDV RNA undetectability during long-term bulevirtide monotherapy in patients with HDV-related compensated cirrhosis: a subanalysis of the retrospective multicenter European Study (SAVE-D)
E. Degasperi, M.P. Anolli, L. Gheorghe, M. Chitul, C. Schramm, H. Schmidt, M. Jachs, T. Reiberger, J. Foucher, S. Metivier, M. Buti, A. Palom, G. D’Offizi, F. di Maria, C. Zöllner, F. Tacke, C. Dietz-Fricke, H. Wedemeyer, M. Papatheodoridi, G. Papatheodoridis, I. Carey, K. Agarwal, F. Van Bömmell, M.R. Brunetto, M. Cardoso, E. Rosselli Del Turco, A. Ciancio, S. Lens, Á. Giráldez-Gallego, F. Zoulim, S. Aleman, N. Semmo, A. Mangia, M.N. Hilleret, U. Merle, T.A. Santantonio, N. Coppola, A. Pellicelli, B. Roche, X. Causse, L. D’Alteroche, J. Dumortier, N. Ganne, F. Heluwaert, I. Ollivier, D. Roulot, M. Viganò, A. Loglio, A. Federico, F. Pileri, M. Maracci, M. Tonnini, J.P. Arpurt, K. Barange, E. Billaud, S. Pol, A. Gervais, A. Minello, I. Rosa, M. Puoti, P. Lampertico
P55
3 years of bulevirtide monotherapy in patients with HDV-related compensated cirrhosis: virologial outcomes and safety data from the retrospective multicenter European Study (SAVE-D)
E. Degasperi, M.P. Anolli, C. Schramm, H. Schmidt, C. Dietz-Fricke, H. Wedemeyer, C. Zöllner, F. Tacke, G. D’Offizi, F. di Maria, M. Jachs, T. Reiberger, M. Papatheodoridi, G. Papatheodoridis, E. Rosselli Del Turco, D. Roulot, M.R. Brunetto, A. Mangia, A. Loglio, T.A. Santantonio, M. Maracci, N. Semmo, M. Cardoso, P. Lampertico
P56
Safety, effectiveness and clinical outcomes in patients with chronic Hepatitis Delta treated with bulevirtide monotherapy: a pooled analysis on 689 patients enrolled in the SAVE-D and D-SHIELD studies
E. Degasperi, M.P. Anolli, G. D’Offizi, A. Ciancio, L. Gheorghe, A. Loglio, M.R. Brunetto, C. Schramm, S. Zaltron, T. Reiberger, M. Cardoso, J. Foucher, M. Buti, M. Milella, A. Federico, E.R. Del Turco, T.A. Santantonio, K. Agarwal, L. Turco, C. Zöllner, H. Wedemeyer, G. Papatheodoridis, L. Sarmati, L. Marinaro, F. Van Bömmel, F.P. Russo, A. Gori, I. Maida, A. Gasbarrini, P. Toniutto, F. Morisco, A. Romano, A. Mangia, E. Giannini, M. Maracci, S. De Nicola, B. Pinchera, M. Puoti, S. Lens, Á. Giráldez-Gallego, L. Crocè, N. Semmo, F. Zoulim, F. Pileri, S. Aleman, A. Pan, U. Merle, P. Pozzoni, R. Zampino, N. Coppola, M. Persico, M.N. Hilleret, P. Caraceni, M. Tonnini, B. Roche, X. Causse, L. D’Alteroche, J. Dumortier, N. Ganne, F. Heluwaert, I. Ollivier, D. Roulot, A. Soria, I. Arena, A. Pellicelli, E. Grassi, P. Vitiello, J.P. Arpurt, K. Barange, E. Billaud, S. Pol, A. Gervais, A. Minello, I. Rosa, V. Esposito, P. Lampertico
P57
Health Disparities in Hepatitis Delta Management: A Case Series on Improving Patient Access to Bulevirtide Therapy
O. Geoghegan, A. Elsharkawy, L. Horobin, R. Oakley, S. Shah
P58
Impact of Bulevirtide Therapy on Physician-Reported Disease Severity Among Patients With Hepatitis Delta: Findings From a Real-World Survey in Europe
M. Buti, F. Hennessy, T. Pennant, D. Graham, F. Barrable, C. Burk, C. Kim, M. Rock, P. Lampertico
P59
Patient-Reported Outcomes Measuring an Individual’s Overall Self-Rated Health After Long-Term Treatment With Bulevirtide 2 mg for Chronic Hepatitis Delta in the Phase 3 MYR301 Trial
M. Buti, H. Wedemeyer, S. Aleman, V. Chulanov, V. Morozov, O. Sagalova, T. Stepanova, R.G. Gish, A. Lloyd, D. Manuilov, A.H. Lau, A.O. Osinusi, M. Rock, C. Kim, S. Pandey, B. Singh, P. Lampertico
P60
Achieving Undetectable Hepatitis Delta Virus RNA at End of Therapy With Bulevirtide 10 mg/Day With or Without PegIFN Is Strongly Associated With Posttreatment Virologic Response in Chronic Hepatitis Delta
M. Buti, H. Wedemeyer, S. Aleman, V. Chulanov, V. Morozov, O. Sagalova, T. Stepanova, R.G. Gish, A. Lloyd, D. Manuilov, A.H. Lau, A.O. Osinusi, M. Rock, C. Kim, S. Pandey, B. Singh, P. Lampertico
P62
Viral Dynamics After Achieving Undetectable HDV RNA With Bulevirtide Monotherapy in Study MYR301
P. Lampertico, S. Aleman, M. Brunetto, P. Bogomolov, V. Chulanov, T. Stepanova, A. Lichtman, D. Manuilov, Z. Wang, M. Cornberg, S. Zeuzem, H. Wedemeyer
P63
Quality of life improves during antiviral therapy with bulevirtide
J.C. Eichholz, C. Dietz-Fricke, S.K. Mrowietz, K. Dinkelborg, K. Port, H. Wedemeyer, K. Deterding
P64
Response-guided bulevirtide treatment: Long-term outcomes observed in the nationwide Austrian hepatitis D cohort study
M. Hintersteininger, M. Schwarz, C. Schwarz, M. Panzer, N. Pfisterer, N. Loschko, L. Hartl, L. Dorn, H. Laferl, M. Trauner, A.F. Stättermayer, M. Mandorfer, I. Graziadei, A. Maieron, A. Moschen, E. Aigner, V. Stadlbauer, C. Madl, S. Aberle, H. Zoller, M. Gschwantler, T. Reiberger, M. Jachs
P65
Serum Bile Acids Do Not Reflect Antiviral Response to Bulevirtide in HDV Infection
M. Hintersteininger, M. Schwarz, P. Schwabl, L. Hartl, L. Balcar, B.S. Hofer, N. Dominik, G. Kramer, C. Sebesta, P. Thöne, M. Gschwantler, M. Trauner, M. Mandorfer, T. Reiberger, M. Jachs
P66
Real-World Experience with Bulevirtide in the Management of Chronic Hepatitis Delta
S. Rusch, T. Elger, S. Schmid, T. Schilling, M. Müller-Schilling
P67
Health-related quality of life in patients with chronic hepatitis D receiving bulevirtide and pegylated interferon: interim results from the SEE-D clinical trial
A. Olsson, S. Cederberg, K. Lindahl, S. Aleman
P68
Virological and biochemical responses of combination treatment with bulevirtide and pegylated interferon up to 72 weeks in chronic hepatitis D patients with advanced fibrosis/cirrhosis: interim results from SEE-D trial
K. Lindahl, H. Kamal, K. Århem, S. Cederberg, A. Olsson, N. Björkström, S. Aleman
P69
Lonafarnib for Chronic Hepatitis Delta (CHD): What is next?
R. Haddadin, X. Hua, L. Kawas, J. Glenn, R. Gish
P70
Mathematical modeling of HDV RNA, ALT and HBsAg kinetics suggests a dual mode of action of peginterferon lambda: Insights from the LIMT-1 Study
A. Mhlanga, L. Shekhtman, S. Duehren, S.J. Cotler, S.S. Hamid, Y. Lurie, E. Gane, A. Nevo-Shor, D. Yardeni, J. Glenn, H. Dahari, O. Etzion
P71
Modeling suggests that 2 mg/day bulevirtide monotherapy efficacy is suboptimal in most HDV-infected patients with compensated cirrhosis and CSPH
A. Mhlanga, L. Shekhtman, O. Wasserman, A. Goyal, E. Degasperi, M.P. Anolli, S. Colonia Uceda Renteria, D. Sambarino, M. Borghi, R. Perbellini, F. Facchetti, A. Callegaro, S.J. Cotler, H. Dahari, P. Lampertico
P72
Influence of Nucleos(t)ide Analogue Use With Bulevirtide on Treatment Outcomes in Chronic Hepatitis Delta
P. Lampertico, M. Brunetto, M. Buti, S. Aleman, P. Bogomolov, V. Chulanov, N. Mamonova, V. Morozov, O. Sagalova, T. Stepanova, R.C. Mercier, M. Li, A. Lichtman, D. Manuilov, H. Wedemeyer, T. Asselah, F. Zoulim
P73
Impact of Prior Interferon Exposure on the Efficacy of Bulevirtide-Based Therapy in Chronic Hepatitis D: a Pooled Analysis From Phase 2 and 3 Studies
M. Buti, F. Zoulim, V. Chulanov, P. Lampertico, H. Wedemeyer, M. Brunetto, A. Streinu-Cercel, T. Asselah, S. Lazar, T. Stepanova, V. Morozov, R.C. Mercier, A. Lichtman, D. Manuilov, S. Yalamanchili, M. Li, S. Aleman
P74
Virological and biochemical responses to initial and retreatment bulevirtide monotherapy in chronic hepatitis D
K. Deterding, L. Shekhtmann, S.J. Cotler, E. Degasperi, P. Lampertico, D. Sambarino, L. Sandmann, K. Port, S, Aleman, A. Olsen, M. Jachs, T. Reiberger, M. Brunetto⁷, G. Ricco, H. Dahari, H. Wedemeyer
P75
Characterisation of HDV RNA, HBsAg and ALT kinetics in patients treated with bulevirtide and pegylated interferon for 60 weeks in the SEE-D trial
E. Zavalis, K. Lindahl, S. Cederberg, A. Olsson, N. Björkström, P. Lampertico, H. Wedemeyer, H. Dahari, S. Aleman
P76
Therapeutic drug monitoring of bulevirtide plasma levels: a cross-sectional analysis in chronic Hepatitis Delta patients
E. Degasperi, A. De Nicolò, D. Sambarino, A. Palermiti, A. Manca, M.P. Anolli, M. Borghi, R. Perbellini, R. Soffredini, S. Monico, F. Facchetti, A. D’Avolio, P. Lampertico
P77
Bile acid profile modifications in patients with chronic hepatitis D receiving bulevirtide therapy
C. Stern, A. Desmons, M. Girard
